House Bill 1011, the North Carolina Compassionate Care Act, would create a comprehensive state medical cannabis program in Chapter 90 of the General Statutes. The bill establishes a new regulatory framework for qualifying patients with specified debilitating medical conditions, including cancer, epilepsy, HIV/AIDS, ALS, Crohn’s disease, sickle cell anemia, Parkinson’s disease, PTSD, multiple sclerosis, cachexia, terminal illness, hospice care, and other conditions added by a new advisory board. Patients would need a physician’s written certification and a registry identification card issued by the Department of Health and Human Services to lawfully obtain and use medical cannabis.
The bill creates two new state bodies: a Compassionate Use Advisory Board to review and add qualifying conditions, and a Medical Cannabis Production Commission to license and oversee suppliers, production facilities, medical cannabis centers, testing laboratories, and the statewide seed-to-sale tracking system. It also imposes physician training, patient monitoring, product testing, packaging, labeling, security, advertising, and recordkeeping requirements, and it limits sales to registered patients and caregivers. The bill authorizes up to 10 supplier licenses, up to 5 independent testing laboratories, and requires suppliers to operate under detailed location, ownership, and compliance rules.
HB1011 would also amend several existing statutes to align state law with the medical cannabis program. It exempts medical cannabis sales to registry cardholders from state retail sales and use tax, excludes regulated medical cannabis products from certain statutory definitions of “drug” and “food,” and revises marijuana and controlled-substance provisions to carve out lawful medical use under the new article. It further provides criminal-law protections for compliant patients, caregivers, physicians, and suppliers, while creating penalties for unauthorized possession, fraudulent identification use, diversion, and other violations. The bill also establishes a dedicated Medical Cannabis Program Fund and directs the program to be self-supporting through fees and revenue assessments rather than General Fund operating support.
The overall sentiment reflected by the bill text is strongly supportive of medical cannabis access, with the findings emphasizing patient health, pain relief, and modern medical research. Because there are no committee transcripts or recorded votes provided, there is no documented floor or committee sentiment to assess beyond the bill’s detailed pro-regulatory structure and its stated public-health purpose. The bill appears designed to present medical cannabis as a tightly controlled health program rather than a recreational legalization measure.
Notable points of contention likely include the scope of qualifying conditions, the extent of state oversight, and the balance between access and diversion control. The bill imposes significant restrictions on physician participation, supplier ownership, advertising, product forms, and location of facilities, which may be intended to address concerns about misuse but could also be viewed as burdensome. Other potentially contentious issues include the residency requirements for suppliers, the 10% monthly gross-revenue fee, the limited number of licenses, the prohibition on smoking and vaping in many public and semi-public places, and the fact that the bill explicitly does not alter nonmedical cannabis laws or create federal-law immunity.
HB1011 would add a new Article 5H to Chapter 90 and make conforming amendments across tax, controlled substances, evidence, and criminal-law provisions. It would legalize and regulate medical cannabis for qualifying patients and caregivers, create a licensing and enforcement structure within DHHS and a new commission, exempt compliant conduct from state criminal penalties, and exempt medical cannabis sales from state sales and use tax. It would also require new rules, registry systems, inspections, testing, labeling, and reporting obligations for physicians, patients, suppliers, and laboratories, while preserving existing prohibitions on nonmedical cannabis and acknowledging that federal law is unchanged.
The bill’s stated purpose and structure indicate a generally favorable sentiment toward medical cannabis access, framed as a public-health measure for patients with serious illnesses. The text repeatedly emphasizes patient protection, safety, and controlled regulation, suggesting support for legalization in a limited medical context rather than broader cannabis reform. No committee discussion or vote history was provided, so there is no recorded legislative debate sentiment beyond the bill’s own findings and design.
Likely points of contention include whether the listed qualifying conditions are too narrow or too broad, whether the physician training and in-person exam requirements are too restrictive, and whether the licensing system is too limited with only 10 suppliers and 5 testing labs. The bill’s residency and ownership requirements for suppliers, the 10% gross-revenue fee, and the prohibition on advertising and many forms of public consumption may also draw criticism from industry advocates or civil-liberties opponents. Public-safety stakeholders may focus on diversion controls, criminal-history checks, and law-enforcement access to the verification system, while patient advocates may focus on access barriers, cost, and the limits on product forms and delivery methods.